Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Status:
Recruiting
Trial end date:
2030-01-03
Target enrollment:
Participant gender:
Summary
The main purpose of this study in participants with PIK3CA-mutated lymphatic malformations
(LyM) is to assess the change in radiological response and symptom severity upon treatment
with alpelisib as compared to placebo.